Healthcare >> CEO Interviews >> October 1, 2001
RUSSELL M. MEDFORD is scientific co-founder, President and Chief
Executive Officer of AtheroGenics, Inc. He has served as a member of
AtheroGenics' Board of Directors since the company's inception in 1993.
Dr. Medford is also a Director of privately held Inhibitex, Inc. and
Somatocor. Dr. Medford serves on the Georgia BioMedical Partnership
Board of Directors and is a member of the Metro Atlanta Biotechnology
Task Force. Dr. Medford is the recipient of the Ernst & Young Southeast
Region 2001 Entrepreneur of the Year award in the emerging category.
Since 1989, Dr. Medford has held a number of academic appointments at
the Emory University School of Medicine, recently as an Associate
Professor of Medicine and Director of Molecular Cardiology, and is
currently Clinical Professor (adjunct) of Medicine. Dr. Medford is a
molecular cardiologist whose research has focused on the molecular basis
of cardiovascular disease. He has published widely in the field of
molecular cardiology and holds 11 US patents. Dr. Medford received a BA
from Cornell University and an MD with Distinction and a PhD in
molecular and cell biology from the Albert Einstein College of Medicine.
Dr. Medford completed his residency in internal medicine at the Beth
Israel Hospital and his fellowship in cardiology at the Brigham and
Women's Hospital and Harvard Medical School, where he also served on the
faculty of Medicine. Profile
AtheroGenics?
Dr. Medford: AtheroGenics is an emerging pharmaceutical company that is
positioning itself to be a leader in
